{"id":"bion-1301","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL6014177","moleculeType":null,"molecularWeight":"427.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BION-1301 binds to FGFR4, a receptor overexpressed in hepatocellular carcinoma, blocking FGF19-FGFR4 signaling that drives tumor proliferation and survival. By inhibiting this pathway, the drug aims to slow or stop cancer cell growth. This approach is particularly relevant in HCC where FGF19-FGFR4 axis activation is a common oncogenic driver.","oneSentence":"BION-1301 is a monoclonal antibody that targets and inhibits FGFR4 (fibroblast growth factor receptor 4) to reduce hepatocellular carcinoma cell growth and survival.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:23.413Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma (HCC), FGFR4-positive"}]},"trialDetails":[{"nctId":"NCT06858319","phase":"PHASE3","title":"Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-28","conditions":"Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases","enrollment":220},{"nctId":"NCT05852938","phase":"PHASE3","title":"A Study of Zigakibart in Adults With IgA Nephropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-07-06","conditions":"IgA Nephropathy, Immunoglobulin A Nephropathy","enrollment":383},{"nctId":"NCT03945318","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-04-08","conditions":"IgA Nephropathy","enrollment":103},{"nctId":"NCT05508204","phase":"PHASE1","title":"Open-label Safety and PK Study of BION-1301 in Japanese Healthy Subjects","status":"COMPLETED","sponsor":"Chinook Therapeutics, Inc.","startDate":"2022-07-19","conditions":"Healthy Volunteer","enrollment":36},{"nctId":"NCT03340883","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)","status":"TERMINATED","sponsor":"Chinook Therapeutics, Inc.","startDate":"2017-11-15","conditions":"Multiple Myeloma","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Zigakibart"],"phase":"phase_3","status":"active","brandName":"BION-1301","genericName":"BION-1301","companyName":"Chinook Therapeutics, Inc.","companyId":"chinook-therapeutics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"BION-1301 is a monoclonal antibody that targets and inhibits FGFR4 (fibroblast growth factor receptor 4) to reduce hepatocellular carcinoma cell growth and survival. Used for Hepatocellular carcinoma (HCC), FGFR4-positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}